文献速递生殖医学妇科

抗苗勒管激素用于诊断和预测绝经:一项系统综述

Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review.
PubMed 文献 · Hum Reprod Update · 2023-01-01

该系统综述检索截至2022年5月31日的文献,纳入41项研究共28858名女性,评估抗苗勒管激素(AMH)诊断绝经、预测绝经及预测/诊断早发性卵巢功能不全(POI)的价值。AMH单独不能精确预测绝经年龄,但极低或检测不到的AMH可能有助于年轻女性POI的早期诊断。

要点

  • 低年龄别AMH浓度与较早绝经年龄相关,但AMH单独不能精确预测绝经年龄。
  • 检测不到AMH对绝经的诊断准确性与FSH升高(>22.3 mIU/ml)相当。
  • 极低或检测不到AMH可能有助于有POI家族史或闭经年轻女性的POI早期诊断。

核心结论

  • 系统综述结果支持使用血清AMH在人群研究中研究绝经年龄。
  • 当前AMH检测灵敏度提高改善了临近绝经预测的准确性,但针对个体患者的诊断用途尚未经过严格检验。
  • 当绝经不临近时,绝经年龄预测仍不精确,但年轻女性极低AMH值具有临床价值,提示POI发生风险增加并可能促进及时诊断。

研究设计与样本

  • 系统综述,检索PubMed、Embase和Cochrane对照试验中心注册库截至2022年5月31日的文献。
  • 共识别3207项研究,最终纳入41项研究,包括28858名女性。
  • 使用无Meta分析的合成方法提取和合成数据,采用队列研究偏倚风险评估工具评估偏倚风险,排除高偏倚风险研究。

主要发现

  • 评估AMH诊断绝经的3项研究中,1项显示检测不到AMH与FSH升高(>22.3 mIU/ml)具有等效诊断准确性。
  • 无研究评估AMH是否可用于缩短正式诊断绝经所需的12个月闭经时间。
  • 评估AMH与绝经 onset 的27项发表研究(n=23835名女性)一般表明,较低的年龄别AMH浓度与较早绝经年龄相关。
  • AMH单独不能精确预测绝经年龄,40岁以下女性的估计值和置信区间范围为2至12年。
  • 有证据表明,检测不到或极低AMH可能有助于有POI家族史或原发/继发闭经的年轻女性POI早期诊断(11项研究,n=4537名女性)。

关键数值与推荐

  • 检测不到AMH与FSH升高(>22.3 mIU/ml)在绝经诊断中具有等效诊断准确性(1项研究)。
  • 40岁以下女性AMH预测绝经年龄的估计值和置信区间范围为2至12年。
  • AMH预测价值随年龄增加而提高,因为预测间隔(至绝经时间)缩短。
  • 检测不到或极低AMH可能有助于有POI家族史或原发/继发闭经年轻女性的POI早期诊断(11项研究,n=4537名女性)。

临床怎么用

  • 系统综述结果支持使用血清AMH在人群研究中研究绝经年龄。
  • 当前AMH检测灵敏度提高改善了临近绝经预测的准确性,但针对个体患者的诊断用途尚未经过严格检验。
  • 年轻女性极低AMH值具有临床价值,提示POI发生风险增加并可能促进及时诊断。

局限性

  • AMH单独不能精确预测绝经年龄,40岁以下女性的估计值和置信区间范围为2至12年。
  • 当绝经不临近时,绝经年龄预测仍不精确。
  • 针对个体患者的诊断用途尚未经过严格检验。
  • 无研究评估AMH是否可用于缩短正式诊断绝经所需的12个月闭经时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The early onset of menopause is associated with increased risks of cardiovascular disease and osteoporosis. As a woman's circulating anti-Müllerian hormone (AMH) concentration reflects the number of follicles remaining in the ovary and declines towards the menopause, serum AMH may be of value in the early diagnosis and prediction of age at menopause. OBJECTIVE AND RATIONALE: This systematic review was undertaken to determine whether there is evidence to support the use of AMH alone, or in conjunction with other markers, to diagnose menopause, to predict menopause, or to predict and/or diagnose premature ovarian insufficiency (POI). SEARCH METHODS: A systematic literature search for publications reporting on AMH in relation to menopause or POI was conducted in PubMed®, Embase®, and the Cochrane Central Register of Controlled Trials up to 31 May 2022. Data were extracted and synthesized using the Synthesis Without Meta-analysis for diagnosis of menopause, prediction of menopause, prediction of menopause with a single/repeat measurement of AMH, validation of prediction models, short-term prediction in perimenopausal women, and diagnosis and prediction of POI. Risk-of-bias was evaluated using the Tool to Assess Risk of Bias in Cohort Studies protocol and studies at high risk of bias were excluded. OUTCOMES: A total of 3207 studies were identified, and 41, including 28 858 women, were deemed relevant and included. Of the three studies that assessed AMH for the diagnosis of menopause, one showed that undetectable AMH had equivalent diagnostic accuracy to elevated FSH (>22.3 mIU/ml). No study assessed whether AMH could be used to shorten the 12 months of amenorrhoea required for a formal diagnosis of menopause. Studies assessing AMH with the onset of menopause (27 publications [n = 23 835 women]) generally indicated that lower age-specific AMH concentrations are associated with an earlier age at menopause. However, AMH alone could not be used to predict age at menopause with precision (with estimates and CIs ranging from 2 to 12 years for women aged <40 years). The predictive value of AMH increased with age, as the interval of prediction (time to menopause) shortened. There was evidence that undetectable, or extremely low AMH, may aid early diagnosis of POI in young women with a family history of POI, and women presenting with primary or secondary amenorrhoea (11 studies [n = 4537]). WIDER IMPLICATIONS: The findings of this systematic review support the use of serum AMH to study the age of menopause in population studies. The increased sensitivity of current AMH assays provides improved accuracy for the prediction of imminent menopause, but diagnostic use for individual patients has not been rigorously examined. Prediction of age at menopause remains imprecise when it is not imminent, although the finding of very low AMH values in young women is both of clinical value in indicating an increased risk of developing POI and may facilitate timely diagnosis.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Nelson SM, Davis SR, Kalantaridou S, et al. Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review. Hum Reprod Update. 2023. PMID: 36651193. doi:10.1093/humupd/dmac045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。